ALLR

Allarity Therapeutics

1.35 USD
+0.00
0.00%
Updated Nov 11, 1:05 PM EST
1 day
0.00%
5 days
-5.59%
1 month
-2.88%
3 months
-69.46%
6 months
-94.35%
Year to date
-99.59%
1 year
-99.53%
5 years
-100.00%
10 years
-100.00%
 

About: Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Employees: 6

0
Funds holding %
of 6,759 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

823% more capital invested

Capital invested by funds: $11.7K [Q1] → $108K (+$96.1K) [Q2]

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

125% more funds holding

Funds holding: 4 [Q1] → 9 (+5) [Q2]

1.37% more ownership

Funds ownership: 0.63% [Q1] → 1.99% (+1.37%) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for ALLR.

Financial journalist opinion

Based on 117 articles about ALLR published over the past 30 days

Charts implemented using Lightweight Charts™